Table 1 Demographic and clinical characteristics of systemic lupus erythematosus patients
From: CD4+CD25-Foxp3+ T cells: a marker for lupus nephritis?
Characteristic | Value |
|---|---|
Age, years, mean ± SD | 40.4 ± 14.5 |
Gender, female/male, n (%) | 56 (91.8%)/5 (8.2%) |
Disease duration years, mean ± SD | 5.4 ± 4.9 |
Anti-ds DNA Ab-positive, n (%) | 23 (62.3%) |
C3, mean ± SD | 90.5 ± 26.6 |
C4, mean ± SD | 14.3 ± 7.1 |
CH50, mean ± SD | 110.6 ± 31.9 |
SLEDAI, mean ± SD | 4.2 ± 4.2 |
ECLAM, mean ± SD | 1.9 ± 1.9 |
SIS, mean ± SD | 3.6 ± 2.9 |
Current prednisone dose, mg/day, mean ± SD | 10.4 ± 15.3 |
Concurrent immunosuppressive therapy, n (%) | |
Hydroxychloroquine | 22 (36.1%) |
Mycophenolate mofetil | 9 (14.8%) |
Cyclophosphamide | 6 (9.8%) |
Azathioprine | 8 (13.1%) |
Methotrexate | 5 (8.2%) |
Organ involvement, n (%) | |
Skin/active | 37 (60.7.1%)/8 (13.1%) |
Hematologic/active | 23 (37.7%)/10 (16.4%) |
Arthritis/active | 22 (36.1%)/3 (4.9%) |
Serositis/active | 8 (13.1%)/2 (3.3%) |
Renal/active | 25 (40.9%)/13 (21.3%) |